Dosing frequency and medication adherence in chronic disease

Journal of Managed Care Pharmacy

Volumn 18, Issue 7, 2012, Pages 527-539

  Coleman, Craig I ^a   Limone, Brendan ^b   Sobieraj, Diana M ^a   Lee, Soyon ^b   Roberts, Matthew S ^b   Kaur, Rajbir ^b   Alam, Tawfikul ^b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC DISEASE; DOSING FREQUENCY; DRUG DOSE REGIMEN; FOLLOW UP; HUMAN; META ANALYSIS; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; POST HOC ANALYSIS; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFERENCE DATABASE; REVIEW; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW;

EID: 84867734437     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2012.18.7.527     Document Type: Review

References (76)

1. Centers for Disease Control and Prevention. Chronic disease prevention and health promotion. Available at: http://www.cdc.gov/nccdphp/. Accessed July 27, 2012.
2. Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009;15(6):e22-33. Available at: http://www.ajmc.com/articles/ AJMC_09JunSaini_Xclusiv_e22to33. Accessed July 27, 2012.
3. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296-310.
4. Kalaian HA, Raudenbush SW. A multivariate mixed linear model for meta-analysis. Psychological Methods. 1996;1(3):227-35.
5. Osterberg L, Blaske T. Adherence to medication. New Engl J Med. 2005;353(5):487-97.
6. Bohachick P, Burke LE, Sereika S, Murali S, Dunbar-Jacob J. Adherence to angiotensin-converting enzyme inhibitor therapy for heart failure. Prog Cardiovasc Nurs. 2002;17(4):160-66.
7. Mevacor (Lovastatin). Merck & Co., Inc. February 2012. Available at: http://www.merck.com/product/usa/pi_circulars/m/mevacor/mevacor_ pi.pdf. Accessed July 27, 2012.
8. Chase TN. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs. 1998;55(Suppl 1):S1-S9.
9. Amsterdam EA. Rationale for intermittent nitrate therapy. Am J Cardiol. 1992;70(17):55G-59G.
10. Clerisme-Beaty EM, Bartlett SJ, Teague WG, et al. The Madison Avenue effect: how drug presentation style influences adherence and outcome in patients with asthma. J Allergy Clin Immunol. 2011;127(2):406-11. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3050545/?tool=pubmed. Accessed July 27, 2012.
11. Doró P, Benko R, Czakó A, Matuz M, Thurzó F, Soós G. Optimal recall period in assessing the adherence to antihypertensive therapy: a pilot study. Int J Clin Pharm. 2011;33(4):690-95.
12. Favrat B, Vaucher P, Herzig L, et al. Oral vitamin B12 for patients suspected of subtle cobalamin deficiency: a multicentre pragmatic randomised controlled trial. BMC Fam Pract. 2011;12:2. Available at: http://www.biomedcentral. com/1471-2296/12/2. Accessed July 27, 2012.
13. Kronish IM, Rieckmann N, Shimbo D, Burg M, Davidson KW. Aspirin adherence, aspirin dosage, and C-reactive protein in the first 3 months after acute coronary syndrome. Am J Cardiol. 2010;106(8):1090-94. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967432/?tool=pubmed. Accessed July 27, 2012.
14. Platt AB, Localio AR, Brensinger CM, et al. Can we predict daily adherence to warfarin? Results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Chest. 2010;137(4):883-89. Available at: http://chestjournal.chestpubs.org/content/137/4/883.long. Accessed July 27, 2012.
15. Stilley CS, Bender CM, Dunbar-Jacob J, Sereika S, Ryan CM. The impact of cognitive function on medication management: three studies. Health Psychol. 2010;29(1):50-55. Available at: http://www.ncbi.nlm.nih.gov/pmc/ articles/PMC2807986/?tool=pubmed. Accessed July 27, 2012.
16. Grosset D, Antonini A, Canesi M, et al. Adherence to antiparkinson medication in a multicenter European study. Mov Discord. 2009;24(6):826-32.
17. Udelson JE, Pressler SJ, Sackner-Bernstein J, et al. Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) Trial. J Card Fail. 2009;15(5):385-93.
18. Yentzer BA, Yelverton CB, Pearce DJ, et al. Adherence to acitretin and home narrowband ultraviolet B phototherapy in patients with psoriasis. J Am Acad Dermatol. 2008;59(4):577-81.
19. Kardas P. Compliance, clinical outcome, and quality of life of patients with stable angina pectoris receiving once-daily betaxolol versus twice daily metoprolol: a randomized controlled trial. Vasc Health Risk Manag. 2007;3(2):235-42. Available at: http://www.dovepress.com/articles. php?article_id=1478. Accessed July 27, 2012.
20. Rand C, Bilderback A, Schiller K, Edelman JM, Hustad CM, Zeiger RS. MIAMI Study Research Group. Adherence with montelukast or fluticasone in a long-term clinical trial: results from the mild asthma montelukast versus inhaled corticosteroid trial. J Allergy Clin Immunol. 2007;119(4):916-23.
21. Grosset KA, Grosset DG. Effect of educational intervention on medication timing in Parkinson's disease: a randomized controlled trial. BMC Neurol. 2007;7:20. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC1931606/pdf/1471-2377-7-20.pdf. Accessed July 27, 2012.
22. Márquez-Contreras E, Martell-Claros N, Gil-Guillén V, et al.; Compliance Group of the Spanish Society of Hypertension (SEE). Efficacy of a home blood pressure monitoring programme on therapeutic compliance in hypertension: the EAPACUM-HTA study. J Hypertens. 2006;24(1):169-75.
23. Charpentier G, Fleury F, Dubroca I, Vaur L, Clerson P. Electronic pillboxes in the evaluation of oral hypoglycemic agent compliance. Diabetes Metab. 2005;31(2):189-95.
24. Kardas P. The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes). Diabetes Obes Metab. 2005;(6):722-28.
25. Tu W, Morris AB, Li J, et al. Association between adherence measurements of metoprolol and health care utilization in older patients with heart failure. Clin Pharmacol Ther. 2005;77(3):189-201. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2577028/?tool=pubmed. Accessed July 27, 2012.
26. Buelow JM, Smith MC. Medication management by the person with epilepsy: perception versus reality. Epilepsy Behav. 2004;5(3):401-06.
27. Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab. 2004;89(3):1117-23. Available at: http://jcem.endojournals.org/content/ 89/3/1117.long. Accessed July 27, 2012.
28. Kardas P; COMPASS Investigators. Comparison of once daily versus twice daily oral nitrates in stable angina pectoris. Am J Cardiol. 2004;94(2):213-16.
29. De Klerk E, Van der Heijde D, Landewé R, van der Tempel H, Urquhart J, van der Linden S. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol. 2003;30(1):44-54. Erratum in: J Rheumatol. 2003;30(2):423.
30. Girvin BG, Johnston GD. Comparison of the effects of a 7-day period of non-compliance on blood pressure control using three different antihypertensive agents. J Hypertens. 2004;22(7):1409-14.
31. Hamilton GA. Measuring adherence in a hypertension clinical trial. Eur J Cardiovasc Nurs. 2003;2(3):219-28.
32. Laporte S, Quenet S, Buchmüller-Cordier A, et al. Compliance and stability of INR of two oral anticoagulants with different half-lives: a randomised trial. Thromb Haemost. 2003;89(3):458-67.
33. Winkler A, Teuscher AU, Mueller B, Diem P. Monitoring adherence to prescribed medication in type 2 diabetic patients treated with sulfonylureas. Swiss Med Wkly. 2002;132(27-28):379-85. Available at: http://www.smw.ch/for-readers/archive/backlinks/?url=/docs/archive200x/2002/27/smw-10036. html. Acessed July 27, 2012.
34. Chung KF, Naya I. Compliance with an oral asthma medication: a pilot study using an electronic monitoring device. Respir Med. 2000;94(9):852-58.
35. Girvin B, Johnston GD. A randomized comparison of a conventional dose, a low dose and alternate-day dosing of bendrofluazide in hypertensive patients. J Hypertens. 1998;16(7):1049-54.
36. Schwed A, Fallab CL, Burnier M, et al. Electronic monitoring of compliance to lipid-lowering therapy in clinical practice. J Clin Pharmacol. 1999;39(4):402-09.
37. Waeber B, Leonetti G, Kolloch R, McInnes GT. Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study. J Hypertens. 1999;17(7):1041-45.
38. Waeber B, Vetter W, Darioli R, Keller U, Brunner HR. Improved blood pressure control by monitoring compliance with antihypertensive therapy. Int J Clin Pract. 1999;53(1):37-38.
39. Mulleners WM, Whitmarsh TE, Steiner TJ. Noncompliance may render migraine prophylaxis useless, but once-daily regimens are better. Cephalalgia. 1998;18(1):52-56.
40. Rivers PH, Ardagh-Walter N, Wright EC. Measurement of anticonvulsant adherence behaviour in the community using a Medication Events Monitoring System (MEMS). Health Care Anal. 1998;6(4):308-16.
41. Leenen FH, Wilson TW, Bolli P, et al. Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoring. Can J Cardiol. 1997;13(10):914-20.
42. Paes AH, Bakker A, Soe-Agnie CJ. Impact of dosage frequency on patient compliance. Diabetes Care. 1997;20(10):1512-17.
43. Vrijens B, Goetghebeur E. Comparing compliance patterns between randomized treatments. Control Clin Trials. 1997;18(3):187-203.
44. De Klerk E, van der Linden SJ. Compliance monitoring of NSAID drug therapy in ankylosing spondylitis, experiences with an electronic monitoring device. Br J Rheumatol. 1996;35(1):60-65. Available at: http://rheumatology. oxfordjournals.org/content/35/1/60.long. Accessed July 27, 2012.
45. Mallion JM, Dutrey-Dupagne C, Vaur L, et al. Benefits of electronic pillboxes in evaluating treatment compliance of patients with mild to moderate hypertension. J Hypertens. 1996;14(1):137-44.
46. Mason BL, Matsuyama JR, Jue SG. Microprocessor-assessed adherence with once- or twice-a-day dosing with Sulfonylurea-no difference. West J Med. 1996;164(2):182. Available at: http://www.ncbi.nlm.nih.gov/pmc/ articles/PMC1303401/?tool=pubmed. Accessed July 27, 2012.
47. Mason B. Anticoagulant clinic warfarin adherence rates and assessment. J Pharm Technol. 1996;12(3):97-101.
48. Straka RJ, Fish JT, Benson SR, Suh JT. Magnitude and nature of noncompliance with treatment using isosorbide dinitrate in patients with ischemic heart disease. J Clin Pharmacol. 1996;36(7):587-94.
49. Cramer J, Vachon L, Desforges C, Sussman NM. Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial. Epilepsia. 1995;36(11):1111-17.
50. Brun J. Patient compliance with once-daily and twice-daily oral formulations of 5-isosorbide mononitrate: a comparative study. J Int Med Res. 1994;22(5):266-72. Erratum in: J Int Med Res. 1994;22(6):350.
51. Kruse W, Rampmaier J, Ullrich G, Weber E. Patterns of drug compliance with medications to be taken once and twice daily assessed by continuous electronic monitoring in primary care. Int J Clin Pharmacol Ther. 1994;32(9):452-57.
52. Steiner TJ, Catarci T, Hering R, Whitmarsh T, Couturier EG. If migraine prophylaxis does not work, think about compliance. Cephalalgia. 1994;14(6):463-64.
53. Kruse W, Nikolaus T, Rampmaier J, Weber E, Schlierf G. Actual versus prescribed timing of lovastatin doses assessed by electronic compliance monitoring. Eur J Clin Pharmacol. 1993;45(3):211-15.
54. Rudd P, Ramesh J, Bryant-Kosling C, Guerrero D. Gaps in cardiovascular medication taking: the tip of the iceberg. J Gen Intern Med. 1993;8(12):659-66.
55. Rudd P, Ahmed S, Zachary V, Barton C, Bonduelle D. Compliance with medication timing: implications from medication trial for drug development and clinical practice. J Clin Res Pharmacoepidemiol. 1992;6(1):15-27.
56. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990;150(9):1881-84.
57. Kruse W, Weber E. Dynamics of drug regimen compliance-its assessment by microprocessor-based monitoring. Eur J Clin Pharmacol. 1990;38(6):561-65.
58. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA. 1989;261(22):3273-77.
59. Eisen SA, Woodward RS, Miller D, Spitznagel E, Windham CA. The effect of medication compliance on the control of hypertension. J Gen Intern Med. 1987;2(5):298-305.
60. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. The Cochrane Collaboration. March 2011. Available at: www.cochrane-handbook.org. Accessed July 27, 2011.
61. Butler RJ, Davis TK, Johnson WG, Gardner HH. Effects of nonadherence with prescription drugs among older adults. Am J Manag Care. 2011;17(2):153-60. Available at: http://www.ajmc.com/publications/ issue/2011/2011-2-vol17-n2/AJMC_11feb_Butler_153to160/. Accessed July 27, 2012.
62. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455-61.
63. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998;279(18):1458-62.
64. Feldman R, Bacher M, Campbell N, Drover A, Chockalingam A. Adherence to pharmacologic management of hypertension. Can J Public Health. 1998;89(5):I16-18.
65. Flack J, Novikov SV, Ferrario CM. Benefits of adherence to anti-hypertensive drug therapy. Eur Heart J. 1996;17(Suppl A):S16-S20. Available at: http://eurheartj.oxfordjournals.org/content/17/suppl_A/16.long. Accessed July 30, 2012.
66. Mallion JM, Baguet JP, Siche JP, Tremel F, De Gaudemaris R. Compliance, electronic monitoring and antihypertensive drugs. J Hypertens Suppl. 1998;16(1):S75-S79.
67. Haynes RB, McKibbon KA, Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet. 1996;348(9024):383-86.
68. McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother. 2002;36(9):1331-36.
69. Senst BL, Achusim LE, Genest RP, et al. Practical approach to determining costs and frequency of adverse drug events in a health care network. Am J Health Syst Pharm. 2001;58(12):1126-32.
70. New England Healthcare Institute. Thinking outside the pillbox: a system-wide approach to improving patient medication adherence for chronic disease. August 12, 2009. Available at: http://www.nehi.net/publications/44/thinking_outside_the_pillbox_a_systemwide_approach_to_improving_patient_medication_adherence_for_chronic_disease. Accessed July 30, 2012.
71. Rodgers PT, Ruffin DM. Medication nonadherence-Part I: The health and humanistic consequences. Manag Care Interface. 1998;11(8):58-60.
72. Schiff GD, Fung S, Speroff T, McNutt RA. Decompensated heart failure: symptoms, patterns of onset, and contributing factors. Am J Med. 2003;114(8):625-30.
73. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166(17):1836-41.
74. Sullivan SD, Krelig DH, Hazlet TK. Noncompliance with medication regimens and subsequent hospitalization: a literature analysis and cost of hospitalization estimate. J Res Pharmaceut Econ. 1990;2(2):19-33.
75. Berg JS, Dischler J, Wagner DJ, Raia JJ, Palmer-Shevlin N. Medication compliance: a healthcare problem. Ann Pharmacother. 1993;27(9 SUPPL):S1-S24.
76. Levy G, Zamacona MK, Jusko WJ. Developing compliance instructions for drug labeling. Clin Pharmacol Ther. 2000;68(6):586-91.